Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 16;7(3):e1000220.
doi: 10.1371/journal.pmed.1000220.

Chronic obstructive pulmonary disease: effects beyond the lungs

Peter J Barnes  1
Affiliations

Chronic obstructive pulmonary disease: effects beyond the lungs

Peter J Barnes. PLoS Med. .

Abstract

Peter Barnes discusses the growing epidemic of chronic obstructive pulmonary disease (COPD), especially in developing countries and among nonsmokers.

PubMed Disclaimer

Conflict of interest statement

PJB is on the Editorial Board of PLoS Medicine.

Figures

Figure 1
Figure 1. Patients with COPD have peripheral lung inflammation that may spill over into the systemic circulation, leading to skeletal muscle weakness and cachexia and increasing propensity to cardiovascular, metabolic, and bone diseases, and depression.
There is an increase in circulating cytokines, including IL-1β, IL-6, IL-18, and TNFα, as well as acute-phase proteins, such as CRP and serum amyloid A. Peripheral lung inflammation may also increase the risk of developing lung cancer. There may be genetic predisposition to developing COPD in smokers, which may be shared with genetic susceptibility to comorbid diseases. Airway obstruction reduces physical activity and causes hypoxia, which may contribute to skeletal muscle weakness as well as to comorbid diseases.
See this image and copyright information in PMC

References

    1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–1185. - PubMed
    1. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J. 2008;32:962–969. - PubMed
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
    1. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–580. - PMC - PubMed
    1. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med. 2007;7:13. - PMC - PubMed

MeSH terms